主页 > 医药科学 >
【drug-news】Prasugrel对比试验显示降低糖尿病患者
Sunday August 31, 9:31 am ET
- Sub-group analysis of landmark trial showed prasugrel substantially
reduced risk of heart attack and stent thrombosis compared with clopidogrel
among ACS patients with diabetes
MUNICH, Germany, August 31 /PRNewswire/ -- Patients who were diabetic and diagnosed with acute coronary syndromes (ACS) were 40 percent less likely to suffer a heart attack if they were treated with prasugrel vs. clopidogrel, according to a sub-group analysis of the TRITON-TIMI 38 trial (8.2 percent vs. 13.2 percent, P<0.001). In addition, according to this same analysis, the combined rate of cardiovascular death, non-fatal heart attack and non-fatal stroke was reduced by 30 percent in diabetes patients treated with prasugrel compared to those treated with clopidogrel (12.2 percent vs. 17.0 percent, P<0.001). In patients without diabetes, there was also improvement in outcomes with prasugrel, with the primary endpoint occurring in 9.2 percent of patients treated with prasugrel and 10.6 percent of patients treated with clopidogrel (P=0.02).
ADVERTISEMENT
The diabetic sub-group analysis was presented today by Stephen Wiviott, M.D., Assistant Professor of Medicine at Harvard Medical School and investigator with the Thrombolysis in Myocardial Infarction (TIMI) Study Group, Brigham & Women's Hospital, Boston, USA, at the Congress of the European Society of Cardiology (ESC) in Munich, Germany. In addition, the manuscript was simultaneously published online in Circulation, the medical journal of the American Heart Association (AHA).
"The results observed from this sub-group analysis showed that antiplatelet therapy with prasugrel resulted in significantly greater reduction of cardiovascular events among patients with diabetes when compared to those who were treated with clopidogrel," said Wiviott.
The reduction of cardiovascular events was consistent across the sub-group of diabetes patients regardless of diabetic therapies (insulin versus no insulin). The study showed a significant relative risk reduction in the primary endpoint of cardiovascular death, non-fatal heart attack and non-fatal stroke with prasugrel, 37 percent for insulin treated and 26 percent (P=0.001) for non-insulin treated diabetics. There was also a significantly lower rate of stent thrombosis among diabetes patients treated with prasugrel, resulting in a 48 percent relative risk reduction in stent thrombosis compared with clopidogrel (3.6 percent vs. 2.0 percent, P=0.007).
"These findings are interesting in view of previous studies that showed higher levels of platelet aggregation in insulin-treated diabetes patients after dual antiplatelet therapy compared to diabetes patients not treated with insulin," said Dr. Wiviott.
The main TRITON-TIMI 38 clinical trial, previously published in the New England Journal of Medicine in November 2007 (Vol. 357, No. 20), compared prasugrel with clopidogrel in patients with ACS undergoing percutaneous coronary intervention (PCI). In the primary analysis of the trial, prasugrel reduced the risk of the composite endpoint of cardiovascular death, heart attack or stroke by 19 percent, with an increased risk of major bleeding compared with clopidogrel (2.4 percent vs. 1.8 percent).(1)
In this sub analysis, the rates of major bleeding events were similar for prasugrel (2.5 percent) and clopidogrel (2.6 percent) among patients with diabetes, regardless of diabetes therapies (insulin versus no insulin).
About Diabetes in Patients with ACS
Among patients with ACS, those with diabetes are at a higher risk for subsequent cardiovascular events, including death.(2) Several mechanisms may increase the risk of events in patients with diabetes, including greater frequency of other cardiac risk factors, a greater burden of narrowing of the arteries (atherosclerotic disease), high blood sugar (hyperglycemia), inflammation, and a greater tendency toward blood clots (thrombosis).(3)(4) (5)
About Prasugrel
Daiichi Sankyo Company, Limited (TSE: 4568 - News) and Eli Lilly and Company (NYSE: LLY - News) are co-developing prasugrel, an investigational oral antiplatelet agent invented by Daiichi Sankyo and its Japanese research partner Ube Industries, Ltd., as a potential treatment, initially for patients with acute coronary syndrome undergoing PCI. Prasugrel works by inhibiting platelet activation and subsequent aggregation by blocking the P2Y12 adenosine diphosphate (ADP) receptor on the platelet surface. Antiplatelet agents prevent platelets from clumping or sticking together, which can result in clogged arteries and may lead to heart attack or stroke. 是个好消息,学习了 这对礼来真是好消息！ 估计FDA批准该药上市应该不成为问题 看来又会成为大力推广的对象了 对患者和商家多是好消息,不能单看一面
阅读本文的人还阅读：
作者:admin@医学,生命科学 2010-11-12 17:11
医学,生命科学网